Future opportunities for the diagnosis and treatment of prostate cancer

Prostate Cancer and Prostatic Diseases
R W G Watson, J A Schalken

Abstract

Despite recent advances, current diagnostic tests and treatment of prostate cancer have limitations. In the last few years, numerous biomolecules have been investigated with the aim of improving diagnosis, including kallikrein-like proteases, growth factors and neuroendocrine markers. Analysis of susceptibility genes has also been a focus of attention. Extensive research into new therapeutic approaches is also underway, including targeting angiogenesis, immune regulation and stromal-epithelial interactions. Gene therapy, gene chip technology and proteomics have emerged as promising innovations. The host of novel diagnostic markers and therapies require appropriate validation, both phenotypical and functional. A further consideration is the need to re-evaluate clinical trial design and end points to facilitate progression of promising targets through the clinical trial process. Overall, the outlook for the treatment of prostate cancer looks promising, with any advances likely to require both a multimodal and multidisciplinary approach.

References

Aug 5, 1999·Journal of the National Cancer Institute·UNKNOWN Breast Cancer Linkage Consortium
Dec 14, 1999·The American Journal of Pathology·A M De MarzoW G Nelson
Feb 15, 2001·Nature Genetics·S V TavtigianL A Cannon-Albright
Aug 31, 2001·European Urology·G AusUNKNOWN EAU Working Group on Oncological Urology
Jan 24, 2002·Cancer Letters·Ugo CavallaroGerhard Christofori
Jan 25, 2002·Molecular Carcinogenesis·Mamoun AhramMichael R Emmert-Buck
Apr 17, 2002·Expert Opinion on Biological Therapy·Heidi HörigHoward L Kaufman
Jul 9, 2002·Investigational New Drugs·Gary R Hudes
Sep 19, 2002·Journal of the National Cancer Institute·Deborah ThompsonUNKNOWN Breast Cancer Linkage Consortium
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Oct 17, 2002·Journal of the National Cancer Institute·Emanuel F PetricoinLance A Liotta
Dec 19, 2002·Surgical Oncology Clinics of North America·Mitchell S SteinerRavi D Chauhan
Jan 29, 2003·Cancer Genetics and Cytogenetics·Ratna ChakrabartiMegan Muroski
Feb 6, 2003·International Journal of Cancer. Journal International Du Cancer·Wouter KorverEmma Lees
Mar 20, 2003·Current Drug Targets·Diana Bello-DeOcampo, Donald J Tindall
Mar 22, 2003·Lancet·Angelo M DeMarzoJonathan I Epstein
Jul 17, 2003·Journal of the National Cancer Institute·Ian ThompsonSusan L Naylor
Nov 11, 2003·Urology·Jack A Schalken, Geert van Leenders
Nov 12, 2003·The Journal of Urology·David M NanusNeil H Bander
Aug 11, 2004·Urology·Yves FradetCamille Chypre

❮ Previous
Next ❯

Citations

Mar 5, 2010·BMC Medical Informatics and Decision Making·Caroline S DorfmanKathryn L Taylor
Aug 19, 2006·Journal of Clinical Gastroenterology·Irvin M ModlinAnthony K C Chan
Jul 1, 2007·Medical Journal, Armed Forces India·R LakhtakiaS K Nema
Jun 14, 2008·The Journal of Steroid Biochemistry and Molecular Biology·Marie-Odile Joly-PharabozJean André
Dec 20, 2005·BJU International·Jack A Schalken

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.